{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:00:12Z","timestamp":1788325212784,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T00:00:00Z","timestamp":1268179200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s12185-010-0528-6","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T04:47:22Z","timestamp":1268110042000},"page":"501-508","source":"Crossref","is-referenced-by-count":55,"title":["Severe hypogammaglobulinemia persisting for 6\u00a0years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis"],"prefix":"10.1007","volume":"91","author":[{"given":"Erika","family":"Irie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kameoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,10]]},"reference":[{"key":"528_CR1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"key":"528_CR2","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1997;15:3266\u201374.","journal-title":"J Clin Oncol"},{"key":"528_CR3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.bmt.1705463","volume":"38","author":"J Shortt","year":"2006","unstructured":"Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2006;38:433\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"528_CR4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2141.2003.04446.x","volume":"122","author":"A Shimoni","year":"2003","unstructured":"Shimoni A, et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin\u2019s lymphoma. Br J Haematol. 2003;122:457\u201364.","journal-title":"Br J Haematol"},{"key":"528_CR5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","volume":"103","author":"SM Horwitz","year":"2004","unstructured":"Horwitz SM, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103:777\u201383.","journal-title":"Blood"},{"key":"528_CR6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1704307","volume":"33","author":"S Imashuku","year":"2004","unstructured":"Imashuku S, et al. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant. 2004;33:129\u201330.","journal-title":"Bone Marrow Transplant"},{"key":"528_CR7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0609.2006.00693.x","volume":"77","author":"M Nishio","year":"2006","unstructured":"Nishio M, et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol. 2006;77:226\u201332.","journal-title":"Eur J Haematol"},{"key":"528_CR8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.282","volume":"23","author":"SA Miles","year":"2005","unstructured":"Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol. 2005;23:247\u20138.","journal-title":"J Clin Oncol"},{"key":"528_CR9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/07357900701809068","volume":"26","author":"AR Walker","year":"2008","unstructured":"Walker AR, et al. Profound hypogammaglobulinemia 7\u00a0years after treatment for indolent lymphoma. Cancer Invest. 2008;26:431\u20133.","journal-title":"Cancer Invest"},{"key":"528_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2141.2007.06584.x","volume":"137","author":"M Nishio","year":"2007","unstructured":"Nishio M, et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol. 2007;137:349\u201354.","journal-title":"Br J Haematol"},{"key":"528_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0609.2008.01174.x","volume":"82","author":"M Nishio","year":"2009","unstructured":"Nishio M, et al. FCGR3A-158V\/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin\u2019s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol. 2009;82:143\u20137.","journal-title":"Eur J Haematol"},{"key":"528_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.1995.tb06630.x","volume":"102","author":"A Saxon","year":"1995","unstructured":"Saxon A, et al. B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1\/fas), diminished CD38 expression, and undergo enhanced apoptosis. Clin Exp Immunol. 1995;102:17\u201325.","journal-title":"Clin Exp Immunol"},{"key":"528_CR13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V82.1.192.bloodjournal821192","volume":"82","author":"JS Jaffe","year":"1993","unstructured":"Jaffe JS, Strober W, Sneller MC. Functional abnormalities of CD8+ T cells define a unique subset of patients with common variable immunodeficiency. Blood. 1993;82:192\u2013201.","journal-title":"Blood"},{"key":"528_CR14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.V76.10.2046.2046","volume":"76","author":"JJ Wright","year":"1990","unstructured":"Wright JJ, et al. Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. Blood. 1990;76:2046\u201351.","journal-title":"Blood"},{"key":"528_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2249.1992.tb05826.x","volume":"90","author":"E Baumert","year":"1992","unstructured":"Baumert E, et al. Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 1992;90:25\u201330.","journal-title":"Clin Exp Immunol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0528-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0528-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0528-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T17:15:43Z","timestamp":1591118143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0528-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,10]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0528-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,10]]}}}